Citations (144)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (16)
Tomislav Majić, Lasse Brandt & Christiane Montag. (2022) Anxiety-related Symptoms following the Sporadic Use of Ecstasy – A Case Study. Journal of Psychoactive Drugs 54:4, pages 378-385.
Read now
Read now
E. Papaseit, M. Torrens, C. Pérez-Mañá, R. Muga & M. Farré. (2018) Key interindividual determinants in MDMA pharmacodynamics. Expert Opinion on Drug Metabolism & Toxicology 14:2, pages 183-195.
Read now
Read now
Torsten Passie & Udo Benzenhöfer. (2016) The History of MDMA as an Underground Drug in the United States, 1960–1979. Journal of Psychoactive Drugs 48:2, pages 67-75.
Read now
Read now
Timothy Amoroso. (2015) The Psychopharmacology of ±3,4 Methylenedioxymethamphetamine and its Role in the Treatment of Posttraumatic Stress Disorder. Journal of Psychoactive Drugs 47:5, pages 337-344.
Read now
Read now
Andrew C. Parrott. (2014) The Potential Dangers of Using MDMA for Psychotherapy. Journal of Psychoactive Drugs 46:1, pages 37-43.
Read now
Read now
Jakob Demant, Signe Ravn & Sidsel Kirstine Thorsen. (2010) Club studies: methodological perspectives for researching drug use in a central youth social space. Leisure Studies 29:3, pages 241-252.
Read now
Read now
FirasH. Kobeissy, MeghanB. O'Donoghue, ErinC. Golden, StephenF. Larner, Zhiqun Zhang & MarkS. Gold. (2006) Performance Enhancement and Adverse Consequences of MDMA. Journal of Addictive Diseases 25:sup1, pages 47-59.
Read now
Read now
Karen McElrath. (2005) MDMA and Sexual Behavior: Ecstasy Users' Perceptions About Sexuality and Sexual Risk. Substance Use & Misuse 40:9-10, pages 1461-1477.
Read now
Read now
FranzX. Vollenweider, MatthiasE. Liechti, Alex Gamma, George Greer & Mark Geyer. (2002) Acute Psychological and Neurophysiological Effects of MDMA in Humans. Journal of Psychoactive Drugs 34:2, pages 171-184.
Read now
Read now
Alonso G. Montoya, Renée Sorrentino, Scott E. Lukas & Bruce H. Price. (2002) Long-Term Neuropsychiatric Consequences of "Ecstasy" (MDMA): A Review. Harvard Review of Psychiatry 10:4, pages 212-220.
Read now
Read now
AlanaR. Pentney. (2001) An Exploration of the History and Controversies Surrounding MDMA and MDA. Journal of Psychoactive Drugs 33:3, pages 213-221.
Read now
Read now
David McDowell. (2000) Gay Men, Lesbians and Substances of Abuse and the “Club and Circuit Party Scene”. Journal of Gay & Lesbian Psychotherapy 3:3-4, pages 37-57.
Read now
Read now
Charles S. Grob. (2000) Deconstructing Ecstasy: The Politics Of Mdma Research. Addiction Research 8:6, pages 549-588.
Read now
Read now
N. Burns, H. J. Olverman, P. A. T. Kelly & B. C. Williams. (1996) Effects of ecstasy on aldosterone secretion in the rat in vivo and in vitro.. Endocrine Research 22:4, pages 601-606.
Read now
Read now
MichaelJ. Cuomo, PaulG. Dyment & VictoriaM. Gammino. (1994) Increasing Use of “Ecstasy“ (MDMA) and other Hallucinogens on a College Campus. Journal of American College Health 42:6, pages 271-274.
Read now
Read now
Arthur Hastings. (1994) Some Observations on MDMA Experiences Induced Through Posthypnotic Suggestion. Journal of Psychoactive Drugs 26:1, pages 77-83.
Read now
Read now
Articles from other publishers (128)
Brian A. Baldo. (2024) The entactogen 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) as a treatment aid in psychotherapy and its safety concerns. Archives of Toxicology.
Crossref
Crossref
Maraine Catarina Tadini, Antônio José Ipólito & Marcelo Firmino de Oliveira. (2023) Voltammetric MDMA Analysis of Seized Ecstasy Samples. Psychoactives 2:4, pages 359-372.
Crossref
Crossref
Sedat Karabulut, Harpreet Kaur & James W. Gauld. (2023) Applications and Potential of In Silico Approaches for Psychedelic Chemistry. Molecules 28:16, pages 5966.
Crossref
Crossref
Katie D. Lewis, Glenn A. Pullella, Han Chern Loh, Brian W. Skelton, Gavin R. Flematti & Matthew J. Piggott. (2023) Synthesis of R- and S-MDMA via nucleophilic ring-opening of homochiral N-tosylaziridines. Australian Journal of Chemistry 76:5, pages 299-310.
Crossref
Crossref
Romain Nardou, Edward Sawyer, Young Jun Song, Makenzie Wilkinson, Yasmin Padovan-Hernandez, Júnia Lara de Deus, Noelle Wright, Carine Lama, Sehr Faltin, Loyal A. Goff, Genevieve L. Stein-O’Brien & Gül Dölen. (2023) Psychedelics reopen the social reward learning critical period. Nature 618:7966, pages 790-798.
Crossref
Crossref
Ruben F. Kranenburg, Henk-Jan Ramaker, Yannick Weesepoel, Peter W.F. Arisz, Peter H.J. Keizers, Annette van Esch, Cathelijne Zieltjens – van Uxem, Jorrit D.J. van den Berg, Janneke W. Hulshof, Sjors Bakels, Anouk M. Rijs & Arian C. van Asten. (2023) The influence of water of crystallization in NIR-based MDMA·HCl detection. Forensic Chemistry 32, pages 100464.
Crossref
Crossref
Markéta Nowaková, Bořek Trávníček, Michal Frelich & Jan Pavlíček. (2023) Acute liver failure after MDMA (Ecstasy) intoxication. Pediatrie pro praxi 24:1, pages 53-56.
Crossref
Crossref
Luis Henríquez-Hernández, Jaime Rojas-Hernández, Domingo Quintana-Hernández & Lucas Borkel. (2023) Hofmann vs. Paracelsus: Do Psychedelics Defy the Basics of Toxicology?—A Systematic Review of the Main Ergolamines, Simple Tryptamines, and Phenylethylamines. Toxics 11:2, pages 148.
Crossref
Crossref
Ruben F. Kranenburg, Henk-Jan Ramaker & Arian C. van Asten. (2022) Portable near infrared spectroscopy for the isomeric differentiation of new psychoactive substances. Forensic Science International 341, pages 111467.
Crossref
Crossref
Mitchell D. Arnovitz, Andrew J. Spitzberg, Ashkhan J. Davani, Nehal P. Vadhan, Julie Holland, John M. Kane & Timothy I. Michaels. (2022) MDMA for the Treatment of Negative Symptoms in Schizophrenia. Journal of Clinical Medicine 11:12, pages 3255.
Crossref
Crossref
Anne-Laure Pélissier-Alicot, Pascal Kintz, Alice Ameline, Caroline Sastre, Valérie Baillif-Couniou & Georges Leonetti. (2022) Soumission chimique impliquant la MDMA : à propos d’un cas inhabituel. Toxicologie Analytique et Clinique 34:2, pages 127-131.
Crossref
Crossref
Aryan Sarparast, Kelan Thomas, Benjamin Malcolm & Christopher S. Stauffer. (2022) Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology 239:6, pages 1945-1976.
Crossref
Crossref
Justin Cormick, James F. Carter, Timothy Currie, Carney Matheson & Sarah L. Cresswell. (2022) Isotope fractionation during the synthesis of MDMA.HCl from helional. Forensic Chemistry 28, pages 100406.
Crossref
Crossref
Jay B. Nair, Linda Hakes, Berra Yazar-Klosinski & Kathryn Paisner. (2021) Fully Validated, Multi-Kilogram cGMP Synthesis of MDMA. ACS Omega 7:1, pages 900-907.
Crossref
Crossref
B. Fauvel & P. Piolino. (2021) La psychothérapie assistée par la MDMA dans la prise en charge du syndrome de stress post-traumatique. Psychologie Française 66:4, pages 345-356.
Crossref
Crossref
Ji Hyun Lee, Ok Rim Park, Suresh Mandava, Jemin Kim, Jaun Koo, Jongkook Lee & Hoil Kang. (2020) Identification of a new M-ALPHA analog and MDMA in an illegal health product. Forensic Science International 313, pages 110332.
Crossref
Crossref
Maria A. Aguilar, Maria P. García-Pardo & Andrew C. Parrott. (2020) Of mice and men on MDMA: A translational comparison of the neuropsychobiological effects of 3,4-methylenedioxymethamphetamine (‘Ecstasy’). Brain Research 1727, pages 146556.
Crossref
Crossref
Madeline M. Pantoni & Stephan G. Anagnostaras. (2019) Cognitive Effects of MDMA in Laboratory Animals: A Systematic Review Focusing on Dose. Pharmacological Reviews 71:3, pages 413-449.
Crossref
Crossref
Kevin Sean Murnane. (2019) Serotonin 2A receptors are a stress response system: implications for post-traumatic stress disorder. Behavioural Pharmacology 30:2 and 3, pages 151-162.
Crossref
Crossref
Joseph J. Palamar & Monica J. Barratt. (2018) Prevalence of reagent test‐kit use and perceptions of purity among ecstasy users in an electronic dance music scene in New York City. Drug and Alcohol Review 38:1, pages 42-49.
Crossref
Crossref
Lee E. Dunlap, Anne M. Andrews & David E. Olson. (2018) Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine. ACS Chemical Neuroscience 9:10, pages 2408-2427.
Crossref
Crossref
Eric Edsinger & Gül Dölen. (2018) A Conserved Role for Serotonergic Neurotransmission in Mediating Social Behavior in Octopus. Current Biology 28:19, pages 3136-3142.e4.
Crossref
Crossref
Shahin Nilchi, Davood Behdarvand, Hoda Lavasani, Mohammadreza Rouini & Yalda H. Ardakani. (2018) Assessment of CYP2D6 re-activation after inhibitory effect of MDMA using tramadol as a probe. Drug Metabolism and Personalized Therapy 33:3, pages 119-125.
Crossref
Crossref
Leopold Hermle & Felix Schuldt. 2018. Handbuch Psychoaktive Substanzen. Handbuch Psychoaktive Substanzen
551
565
.
Andrew C Parrott, Luke A Downey, Carl A Roberts, Cathy Montgomery, Raimondo Bruno & Helen C Fox. (2017) Recreational 3,4-methylenedioxymethamphetamine or ‘ecstasy’: Current perspective and future research prospects. Journal of Psychopharmacology 31:8, pages 959-966.
Crossref
Crossref
Anya K Bershad, Melissa A Miller, Matthew J Baggott & Harriet de Wit. (2016) The effects of MDMA on socio-emotional processing: Does MDMA differ from other stimulants?. Journal of Psychopharmacology 30:12, pages 1248-1258.
Crossref
Crossref
Lewis Jones, Phil Reed & Andrew Parrott. (2016) Mephedrone and 3,4-methylenedioxy-methamphetamine: Comparative psychobiological effects as reported by recreational polydrug users. Journal of Psychopharmacology 30:12, pages 1313-1320.
Crossref
Crossref
Sébastien Ballesta, Gilles Reymond, Matthieu Pozzobon & Jean-René Duhamel. (2016) Effects of MDMA Injections on the Behavior of Socially-Housed Long-Tailed Macaques (Macaca fascicularis). PLOS ONE 11:2, pages e0147136.
Crossref
Crossref
Thomas S. Ray. (2016) Constructing the ecstasy of MDMA from its component mental organs: Proposing the primer/probe method. Medical Hypotheses 87, pages 48-60.
Crossref
Crossref
Leopold Hermle & Felix Schuldt. 2016. Handbuch Psychoaktive Substanzen. Handbuch Psychoaktive Substanzen
1
20
.
Dirk W. Lachenmeier & Jürgen Rehm. (2015) Comparative risk assessment of alcohol, tobacco, cannabis and other illicit drugs using the margin of exposure approach. Scientific Reports 5:1.
Crossref
Crossref
Jenny Bearn & Matthew O'Brien. 2015. The Neuropsychiatric Complications of Stimulant Abuse. The Neuropsychiatric Complications of Stimulant Abuse
205
233
.
Ethan O. Bryson. 2015. Essentials of Pharmacology for Anesthesia, Pain Medicine, and Critical Care. Essentials of Pharmacology for Anesthesia, Pain Medicine, and Critical Care
595
605
.
Randy L. Luciano & Mark A. Perazella. (2014) Nephrotoxic effects of designer drugs: synthetic is not better!. Nature Reviews Nephrology 10:6, pages 314-324.
Crossref
Crossref
Andrew C. Parrott. (2014)
MDMA is certainly damaging after 25 years of empirical research: a reply and refutation of Doblin
et al
. (2014)
. Human Psychopharmacology: Clinical and Experimental 29:2, pages 109-119.
Crossref
Crossref
Ethan O. Bryson. 2014. Anesthesia for Trauma. Anesthesia for Trauma
433
445
.
Andrew C. Parrott. (2013) MDMA, serotonergic neurotoxicity, and the diverse functional deficits of recreational ‘Ecstasy’ users. Neuroscience & Biobehavioral Reviews 37:8, pages 1466-1484.
Crossref
Crossref
Andrew C. Parrott. (2013) Human psychobiology of MDMA or ‘Ecstasy’: an overview of 25 years of empirical research. Human Psychopharmacology: Clinical and Experimental 28:4, pages 289-307.
Crossref
Crossref
Courtney Huff, Nirmal Bhide, Allen Schroering, Bryan K. Yamamoto & Gary A. Gudelsky. (2013) Effect of repeated exposure to MDMA on the function of the 5-HT transporter as assessed by synaptosomal 5-HT uptake. Brain Research Bulletin 91, pages 52-57.
Crossref
Crossref
Roumen Sedefov, Ana Gallegos, Jane Mounteney & Padraigin Kenny. 2013. Novel Psychoactive Substances. Novel Psychoactive Substances
29
54
.
D. F. Rendle & E. J. Glazier. (2012)
Powder diffraction data for methylenedioxymethylamphetamine hydrochloride monohydrate (MDMA.HCl.H
2
O, Ecstasy hydrate)
. Powder Diffraction 27:4, pages 263-265.
Crossref
Crossref
Márcia Carvalho, Helena Carmo, Vera Marisa Costa, João Paulo Capela, Helena Pontes, Fernando Remião, Félix Carvalho & Maria de Lourdes Bastos. (2012) Toxicity of amphetamines: an update. Archives of Toxicology 86:8, pages 1167-1231.
Crossref
Crossref
A.C. Parrott. (2012) MDMA and temperature: A review of the thermal effects of ‘Ecstasy’ in humans. Drug and Alcohol Dependence 121:1-2, pages 1-9.
Crossref
Crossref
A. C. Parrott. 2012. Drug Abuse and Addiction in Medical Illness. Drug Abuse and Addiction in Medical Illness
175
188
.
Samuel DeMariaJr.Jr.. 2012. Perioperative Addiction. Perioperative Addiction
111
128
.
Louis A. Pagliaro & Ann Marie Pagliaro. 2011. Handbook of Child and Adolescent Drug and Substance Abuse. Handbook of Child and Adolescent Drug and Substance Abuse
371
453
.
Susan Dabu-Bondoc, Robert Zhang & Nalini Vadivelu. 2011. Essentials of Pain Management. Essentials of Pain Management
671
697
.
K. S. Murnane, W. E. Fantegrossi, J. R. Godfrey, M. L. Banks & L. L. Howell. (2010) Endocrine and Neurochemical Effects of 3,4-Methylenedioxymethamphetamine and Its Stereoisomers in Rhesus Monkeys. Journal of Pharmacology and Experimental Therapeutics 334:2, pages 642-650.
Crossref
Crossref
Udo Benzenhöfer & Torsten Passie. (2010) Rediscovering MDMA (ecstasy): the role of the American chemist Alexander T. Shulgin. Addiction 105:8, pages 1355-1361.
Crossref
Crossref
Joseph D. Tobias. (2010) Dexmedetomidine to Control Agitation and Delirium from Toxic Ingestions in Adolescents. The Journal of Pediatric Pharmacology and Therapeutics 15:1, pages 43-48.
Crossref
Crossref
Nora Von Ameln & Andreas Von Ameln‐Mayerhofer. (2009) PRECLINICAL STUDY: Atypical development of behavioural sensitization to 3,4‐methylenedioxymethamphetamine (MDMA, ‘Ecstasy’) in adolescent rats and its expression in adulthood: role of the MDMA chirality. Addiction Biology 15:1, pages 35-44.
Crossref
Crossref
Gary A. Gudelsky & Bryan K. Yamamoto. (2008) Actions of 3,4-methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons. Pharmacology Biochemistry and Behavior 90:2, pages 198-207.
Crossref
Crossref
Sunniva Nyberg Karlsen, Olav Spigset & Lars Slørdal. (2007) The Dark Side of Ecstasy: Neuropsychiatric Symptoms after Exposure to 3,4‐Methylenedioxymethamphetamine. Basic & Clinical Pharmacology & Toxicology 102:1, pages 15-24.
Crossref
Crossref
Gino Giannaccini, Laura Betti, Andrea Pirone, Lionella Palego, Ortenzio Fabiani, Laura Fabbrini, Giovanni Mascia, Laura Giusti, Marco Macchia, Mario Giusiani, Claudia Martini & Antonio Lucacchini. (2007) Short-term effects of 3,4-methylen-dioxy-metamphetamine (MDMA) on 5-HT1A receptors in the rat hippocampus. Neurochemistry International 51:8, pages 496-506.
Crossref
Crossref
Ben Sessa & David J. Nutt. (2016) MDMA, politics and medical research: Have we thrown the baby out with the bathwater?. Journal of Psychopharmacology 21:8, pages 787-791.
Crossref
Crossref
Isabelle Billault, Frédérique Courant, Léo Pasquereau, Solène Derrien, Richard J. Robins & Norbert Naulet. (2007) Correlation between the synthetic origin of methamphetamine samples and their 15N and 13C stable isotope ratios. Analytica Chimica Acta 593:1, pages 20-29.
Crossref
Crossref
A. C. Parrott. (2007) The psychotherapeutic potential of MDMA (3,4-methylenedioxymethamphetamine): an evidence-based review. Psychopharmacology 191:2, pages 181-193.
Crossref
Crossref
R. De La GarzaIIII, K. R. Fabrizio & A. Gupta. (2006) Relevance of rodent models of intravenous MDMA self-administration to human MDMA consumption patterns. Psychopharmacology 189:4, pages 425-434.
Crossref
Crossref
Roland W. Freudenmann, Florian Öxler & Sabine Bernschneider‐Reif. (2006) The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents*. Addiction 101:9, pages 1241-1245.
Crossref
Crossref
Claire E. Sterk, Katherine P. Theall & Kirk W. Elifson. (2016) Young Adult Ecstasy use Patterns: Quantities and Combinations. Journal of Drug Issues 36:1, pages 201-228.
Crossref
Crossref
Yossef Itzhak & Syed F. Ali. (2006) Role of nitrergic system in behavioral and neurotoxic effects of amphetamine analogs. Pharmacology & Therapeutics 109:1-2, pages 246-262.
Crossref
Crossref
Elliot J. Krane & Peter J. Davis. 2006. Smith's Anesthesia for Infants and Children. Smith's Anesthesia for Infants and Children
255
271
.
U. Benzenhöfer & T. Passie. (2006) Zur Frühgeschichte von „Ecstasy“The early history of “Ecstasy”. Der Nervenarzt 77:1, pages 95-99.
Crossref
Crossref
Robert G. Carlson, Jichuan Wang, Russel S. Falck & Harvey A. Siegal. (2005) Drug use practices among MDMA/ecstasy users in Ohio: a latent class analysis. Drug and Alcohol Dependence 79:2, pages 167-179.
Crossref
Crossref
Grégory Conductier, Cyril Crosson, René Hen, Joël Bockaert & Valérie Compan. (2005) 3,4-N-Methlenedioxymethamphetamine-Induced Hypophagia is Maintained in 5-HT1B Receptor Knockout Mice, but Suppressed by the 5-HT2C Receptor Antagonist RS102221. Neuropsychopharmacology 30:6, pages 1056-1063.
Crossref
Crossref
A. C. Parrott. (2016) Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy. Journal of Psychopharmacology 19:1, pages 71-83.
Crossref
Crossref
Miriam Williams Boeri, Claire E. Sterk & Kirk W. Elifson. (2016) Rolling beyond Raves: Ecstasy use outside the Rave Setting. Journal of Drug Issues 34:4, pages 831-860.
Crossref
Crossref
Robert G Carlson, Jill A McCaughan, Russel S Falck, Jichuan Wang, Harvey A Siegal & Raminta Daniulaityte. (2004) Perceived adverse consequences associated with MDMA/Ecstasy use among young polydrug users in Ohio: implications for intervention. International Journal of Drug Policy 15:4, pages 265-274.
Crossref
Crossref
Roland W. Freudenmann & Manfred Spitzer. (2006) The Neuropsychopharmacology and Toxicology of 3,4‐methylenedioxy‐N‐ethyl‐amphetamine (MDEA). CNS Drug Reviews 10:2, pages 89-116.
Crossref
Crossref
Fabien Palhol, Catherine Lamoureux, Martine Chabrillat & Norbert Naulet. (2004) 15N/14N isotopic ratio and statistical analysis: an efficient way of linking seized Ecstasy tablets. Analytica Chimica Acta 510:1, pages 1-8.
Crossref
Crossref
Larry C Schmued. (2003) Demonstration and localization of neuronal degeneration in the rat forebrain following a single exposure to MDMA. Brain Research 974:1-2, pages 127-133.
Crossref
Crossref
Erkki Vuori, John A. Henry, Ilkka Ojanperä, Raija Nieminen, Taru Savolainen, Pia Wahlsten & Matti Jäntti. (2003) Death following ingestion of MDMA (ecstasy) and moclobemide. Addiction 98:3, pages 365-368.
Crossref
Crossref
Maristela Ferigolo, Adriana G. da S. Machado, Niara B. Oliveira & Helena M. T. Barros. (2003) Ecstasy intoxication: the toxicological basis for treatment. Revista do Hospital das Clínicas 58:6, pages 332-341.
Crossref
Crossref
José A. Carrión, Àngels Escorsell, Santiago Nogué & Antoni Mas. (2003) Insuficiencia hepática aguda grave por «éxtasis» y trasplante hepático urgente. Medicina Clínica 121:3, pages 118-119.
Crossref
Crossref
Fernando Caudevilla Gálligo. (2003) El «éxtasis»: una revisión de la bibliografía científica sobre la 3,4-metilendioximetanfetamina. Medicina Clínica 120:13, pages 505-515.
Crossref
Crossref
Thomas E. Freese, Karen Miotto & Cathy J. Reback. (2002) The effects and consequences of selected club drugs. Journal of Substance Abuse Treatment 23:2, pages 151-156.
Crossref
Crossref
Stephen C Koesters, Peter D Rogers & Christiana R Rajasingham. (2002) MDMA (‘ecstasy’) and other ‘club drugs’. Pediatric Clinics of North America 49:2, pages 415-433.
Crossref
Crossref
Diana Martinez-Price, Kirsten Krebs-Thomson & Mark Geyer. (2009) Behavioral Psychopharmacology of MDMA and MDMA-Like Drugs: A Review of Human and Animal Studies. Addiction Research & Theory 10:1, pages 43-67.
Crossref
Crossref
Christian J. Teter & Sally K. Guthrie. (2012) A Comprehensive Review of MDMA and GHB: Two Common Club Drugs. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 21:12, pages 1486-1513.
Crossref
Crossref
A. C. Parrott. (2001) Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research. Human Psychopharmacology: Clinical and Experimental 16:8, pages 557-577.
Crossref
Crossref
Grace O’Leary, Jessica Nargiso & Roger D. Weiss. (2001) 3,4-methylenedioxymethamphetamine (mdma): A review. Current Psychiatry Reports 3:6, pages 477-483.
Crossref
Crossref
John B. Murray. (2016) Ecstasy is a Dangerous Drug. Psychological Reports 88:3, pages 895-902.
Crossref
Crossref
JOHN B. MURRAY. (2001) ECSTASY IS A DANGEROUS DRUG. Psychological Reports 88:3, pages 895.
Crossref
Crossref
Zeev N. Kain & Paul G. Barash. (2001) Anesthetic Implications of Drug Abuse. ASA Refresher Courses in Anesthesiology 29:1, pages 159-173.
Crossref
Crossref
MICHAEL SHANNON. (2000) Methylenedioxymethamphetamine (MDMA, “Ecstasy”). Pediatric Emergency Care 16:5, pages 377-380.
Crossref
Crossref
Maristela Ferigolo, Fernanda B. Medeiros & Helena M. T. Barros. (1998) "Êxtase": revisão farmacológica. Revista de Saúde Pública 32:5, pages 487-495.
Crossref
Crossref
Matthew A. Parker, Danuta Marona-Lewicka, Deborah Kurrasch, Alexander T. Shulgin & David E. Nichols. (1998) Synthesis and Pharmacological Evaluation of Ring-Methylated Derivatives of 3,4-(Methylenedioxy)amphetamine (MDA). Journal of Medicinal Chemistry 41:6, pages 1001-1005.
Crossref
Crossref
Joseph A. Barone & Kenneth M. ShermockJRJR. (2016) Designer Drugs of Abuse. Journal of Pharmacy Practice 10:4, pages 292-300.
Crossref
Crossref
G. Huether, D. Zhou & E. R�ther. (1997) Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, ?ecstasy?) and its congeners. Journal of Neural Transmission 104:8-9, pages 771-794.
Crossref
Crossref
Franz Effenberger & Jürgen Jäger. (2006)
Stereoselective Synthesis of (
S
)‐3,4‐Methylenedioxyamphetamines from (
R
)‐Cyanohydrins
. Chemistry – A European Journal 3:8, pages 1370-1374.
Crossref
Crossref
I. De Souza, J. P. Kelly, A. J. Harkin & B. E. Leonard. (2009) An Appraisal of the Pharmacological and Toxicological Effects of a Single Oral Administration of 3,4‐Methylenedioxymethamphetamine (MDMA) in the Rat. Pharmacology & Toxicology 80:5, pages 207-210.
Crossref
Crossref
D. DAVISON & A. C. PARROTT. (1997) Ecstasy (MDMA) in Recreational Users: Self-Reported Psychological and Physiological Effects. Human Psychopharmacology: Clinical and Experimental 12:3, pages 221-226.
Crossref
Crossref
JF Casale, PA Hays & RFX Klein. (1995) Synthesis and Characterization of the 2,3-Methylenedioxyamphetamines. Journal of Forensic Sciences 40:3, pages 391-400.
Crossref
Crossref
THOMAS D. STEELE, UNA D. McCANN & GEORGE A. RICAURTE. (2006) 3,4‐Methylenedioxymethamphetamine (MDMA, “Ecstasy”): pharmacology and toxicology in animals and humans. Addiction 89:5, pages 539-551.
Crossref
Crossref
David M McDowell & Herbert D Kleber. (1994) MDMA: Its History and Pharmacology. Psychiatric Annals 24:3, pages 127-130.
Crossref
Crossref
A.R.W. Forrest, J.H. Galloway, I.D. Marsh, G.A. Strachan & J.C. Clark. (1994) A fatal overdose with 3,4-methylenedioxyamphetamine derivatives. Forensic Science International 64:1, pages 57-59.
Crossref
Crossref
R.J. Renton, J.S. Cowie & M.C.H. Oon. (1993) A study of the precursors, intermediates and reaction by-products in the synthesis of 3,4-methylenedioxymethylamphetamine and its application to forensic drug analysis. Forensic Science International 60:3, pages 189-202.
Crossref
Crossref
Kenji Hashimoto, Harumi Maeda, Katsumi Hirai & Tsuyoshi Goromaru. (1993) Drug effects on distribution of [3H]3,4-methylenedioxymethamphetamine in mice. European Journal of Pharmacology: Environmental Toxicology and Pharmacology 228:5-6, pages 247-256.
Crossref
Crossref
Mark LeSage, Rodney Clark & Alan Poling. (1993) MDMA and memory: the acute and chronic effects of MDMA in pigeons performing under a delayed-matching-to-sample procedure. Psychopharmacology 110:3, pages 327-332.
Crossref
Crossref
Euphrosyne Gouzoulis, Axel Steiger, Martin Ensslin, Arthur Kovar & Leopold Hermle. (1992) Sleep EEG effects of 3,4-methylenedioxyethamphetamine (MDE; “Eve”) in healthy volunteers. Biological Psychiatry 32:12, pages 1108-1117.
Crossref
Crossref
NADIA SOLOWIJ, WAYNE HALL & NICOLE LEE. (2010) Recreational MDMA use in Sydney: a profile of ‘Ecstasy’ users and their experiences with the drug. British Journal of Addiction 87:8, pages 1161-1172.
Crossref
Crossref
James F. Buchanan, Howard E. McKinneyJr.Jr., Gregory N. Hayner & Darryl S. Inaba. 1992. Applied Therapeutics. Applied Therapeutics
1145
1173
.
Masayuki Hiramatsu, Emma DiStefano, Ann S. Chang & Arthur K. Cho. (1991) A pharmacokinetic analysis of 3,4-methylenedioxymethamphetamine effects on monoamine concentrations in brain dialysates. European Journal of Pharmacology 204:2, pages 135-140.
Crossref
Crossref
BK Gan, D Baugh, RH Liu & AS Walia. (1991) Simultaneous Analysis of Amphetamine, Methamphetamine, and 3,4-Methylenedioxymethamphetamine (MDMA) in Urine Samples by Solid-Phase Extraction, Derivatization, and Gas Chromatography/Mass Spectrometry. Journal of Forensic Sciences 36:5, pages 1331-1341.
Crossref
Crossref
Wayne A. Dornan, Jonathan L. Katz & George A. Ricaurte. (1991) The effects of repeated administration of MDMA on the expression of sexual behavior in the male rat. Pharmacology Biochemistry and Behavior 39:3, pages 813-816.
Crossref
Crossref
Dennis J. McKenna, X.-M. Guan & A.T. Shulgin. (1991) 3,4-Methylenedioxyamphetamine (MDA) analogues exhibit differential effects on synaptosomal release of 3H-dopamine and 3H-5-hydroxytryptamine. Pharmacology Biochemistry and Behavior 38:3, pages 505-512.
Crossref
Crossref
John Sharkey, Douglas E. McBean & Paul A. T. Kelly. (1991) Alterations in hippocampal function following repeated exposure to the amphetamine derivative methylenedioxymethamphetamine (?Ecstasy?). Psychopharmacology 105:1, pages 113-118.
Crossref
Crossref
K. Hashimoto & T. Goromaru. (2009)
Reduction of [
3
H]6‐nitroquipazine‐labelled 5‐hydroxytryptamine uptake sites in rat brain by 3,4‐methylenedioxymethamphetamine
. Fundamental & Clinical Pharmacology 4:6, pages 635-641.
Crossref
Crossref
David A. Jerrard. (1990) “Designer drugs” — A current perspective. The Journal of Emergency Medicine 8:6, pages 733-741.
Crossref
Crossref
ERROL B. DE SOUZA, GEORGE BATTAGLIA & THOMAS R. INSEL. (2006)
Neurotoxic Effects of MDMA on Brain Serotonin Neurons: Evidence from Neurochemical and Radioligand Binding Studies
a
. Annals of the New York Academy of Sciences 600:1, pages 682-697.
Crossref
Crossref
EA Julian. (1990) Microcrystalline Identification of Drugs of Abuse: The Psychedelic Amphetamines. Journal of Forensic Sciences 35:4, pages 821-830.
Crossref
Crossref
K. Hashimoto & T. Goromaru. (1990) Reduction of in vivo binding of [3H]paroxetine in mouse brain by 3,4-methylenedioxymethamphetamine. Neuropharmacology 29:7, pages 633-639.
Crossref
Crossref
TAD Cason. (1990) An Evaluation of the Potential for Clandestine Manufacture of 3,4-Methylenedioxyamphetamine (MDA) Analogs and Homologs. Journal of Forensic Sciences 35:3, pages 675-697.
Crossref
Crossref
Kenji Hashimoto, Katsumi Hirai & Tsuyoshi Goromaru. (2006)
Synthesis of racemic, S(+)‐ and R(‐)‐N‐[methyl‐
3
H]3,4‐methylenedioxymethamphetamine
. Journal of Labelled Compounds and Radiopharmaceuticals 28:4, pages 465-469.
Crossref
Crossref
M. Hiramatsu & A.K. Cho. (1990) Enantiomeric differences in the effects of 3,4-methylenedioxymethamphetamine on extracellular monoamines and metabolites in the striatum of freely-moving rats: An in vivo microdialysis study. Neuropharmacology 29:3, pages 269-275.
Crossref
Crossref
E.C. Azmitia, R.B. Murphy & P.M. Whitaker-Azmitia. (1990) MDMA (ecstasy) effects on cultured serotonergic neurons: evidence for Ca2+-dependent toxicity linked to release. Brain Research 510:1, pages 97-103.
Crossref
Crossref
Stephen J. Peroutka. 1990. Ecstasy: The Clinical, Pharmacological and Neurotoxicological Effects of the Drug MDMA. Ecstasy: The Clinical, Pharmacological and Neurotoxicological Effects of the Drug MDMA
53
62
.
George Battaglia, Robert Zaczek & Errol B. De Souza. 1990. Ecstasy: The Clinical, Pharmacological and Neurotoxicological Effects of the Drug MDMA. Ecstasy: The Clinical, Pharmacological and Neurotoxicological Effects of the Drug MDMA
171
199
.
Richard L. Hauger, Itzchak Angel, Aaron Janowsky, Paul Berger & Bridget Hulihan-Giblin. 1990. Application of Basic Neuroscience to Child Psychiatry. Application of Basic Neuroscience to Child Psychiatry
77
100
.
G. Wilkerson & Edythe D. London. (1989) Effects of methylenedioxymethamphetamine on local cerebral glucose utilization in the rat. Neuropharmacology 28:10, pages 1129-1138.
Crossref
Crossref
TA Dal Cason. (1989) The Characterization of Some 3,4-Methylenedioxyphenylisopropylamine (MDA) Analogs. Journal of Forensic Sciences 34:4, pages 928-961.
Crossref
Crossref
Pamela A. Pierce & Stephen J. Peroutka. (1988) Ring-substituted amphetamine interactions with neurotransmitter receptor binding sites in human cortex. Neuroscience Letters 95:1-3, pages 208-212.
Crossref
Crossref
Barbara J. Logan, Richard Laverty, William D. Sanderson & Yet Ben Yee. (1988) Differences between rats and mice in MDMA (methylenedioxymethylamphetamine) neurotoxicity. European Journal of Pharmacology 152:3, pages 227-234.
Crossref
Crossref
George Battaglia, Brian P. Brooks, Chaiyaporn Kulsakdinun & Errol B. De Souza. (1988) Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. European Journal of Pharmacology 149:1-2, pages 159-163.
Crossref
Crossref
Lisa H. Gold & George F. Koob. (1988) Methysergide potentiates the hyperactivity produced by MDMA in rats. Pharmacology Biochemistry and Behavior 29:3, pages 645-648.
Crossref
Crossref
Deborah M. Barnes. (1988) New Data Intensify the Agony Over Ecstasy. Science 239:4842, pages 864-866.
Crossref
Crossref
James F. Buchanan & Christopher R. Brown. (2012) ‘Designer Drugs’. Medical Toxicology 3:1, pages 1-17.
Crossref
Crossref
. (1987) Incidence of Recreational Use of 3,4-Methylenedimethoxymethamphetamine (MDMA, Ecstasy) on an Undergraduate Campus. New England Journal of Medicine 317:24, pages 1542-1543.
Crossref
Crossref